HUP0104593A2 - Csípőbél epesav transzport inhibitor benzotiepin- és nikotinsav-származékok kombinációi szív-érrendszeri indikációkhoz - Google Patents

Csípőbél epesav transzport inhibitor benzotiepin- és nikotinsav-származékok kombinációi szív-érrendszeri indikációkhoz

Info

Publication number
HUP0104593A2
HUP0104593A2 HU0104593A HUP0104593A HUP0104593A2 HU P0104593 A2 HUP0104593 A2 HU P0104593A2 HU 0104593 A HU0104593 A HU 0104593A HU P0104593 A HUP0104593 A HU P0104593A HU P0104593 A2 HUP0104593 A2 HU P0104593A2
Authority
HU
Hungary
Prior art keywords
combinations
transport inhibitor
ileal bile
nicotinic acid
bile acid
Prior art date
Application number
HU0104593A
Other languages
English (en)
Inventor
Daniel T. Connolly
Kevin C. Glenn
Bradley T. Keller
Original Assignee
G.D. Searle Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26811675&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUP0104593(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by G.D. Searle Llc filed Critical G.D. Searle Llc
Publication of HUP0104593A2 publication Critical patent/HUP0104593A2/hu
Publication of HUP0104593A3 publication Critical patent/HUP0104593A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

A találmány szív-érrendszeri terápiás vegyületek kombinációitismerteti szív-érrendszeri betegségek, ezen belülhiperkoleszterinémia, érszűkület vagy hiperlipidémia megelőzésére vagykezelésére. Az ismertetett kombinációk egy csípőbél-epesav transzportinhibitor benzotiepinszármazékot és egy nikotinsavszármazékottartalmaznak. Ó
HU0104593A 1998-12-23 1999-12-17 Combinations of benzothiepine ileal bile acid transport inhibitor and nicotinic acid derivatives for cardiovascular indications HUP0104593A3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11395598P 1998-12-23 1998-12-23
US14255099P 1999-07-07 1999-07-07
PCT/US1999/027950 WO2000038729A1 (en) 1998-12-23 1999-12-17 Combinations of ileal bile acid transport inhibitors and nicotinic acid derivatives for cardiovascular indications

Publications (2)

Publication Number Publication Date
HUP0104593A2 true HUP0104593A2 (hu) 2002-03-28
HUP0104593A3 HUP0104593A3 (en) 2004-10-28

Family

ID=26811675

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0104593A HUP0104593A3 (en) 1998-12-23 1999-12-17 Combinations of benzothiepine ileal bile acid transport inhibitor and nicotinic acid derivatives for cardiovascular indications

Country Status (25)

Country Link
US (1) US20030125316A1 (hu)
EP (1) EP1140191B1 (hu)
JP (1) JP2002533415A (hu)
KR (1) KR20010102963A (hu)
CN (1) CN1338946A (hu)
AR (1) AR037806A1 (hu)
AT (1) ATE226448T1 (hu)
AU (1) AU776952B2 (hu)
BR (1) BR9916567A (hu)
CA (1) CA2356664A1 (hu)
CZ (1) CZ20012343A3 (hu)
DE (1) DE69903661T2 (hu)
DK (1) DK1140191T3 (hu)
EA (1) EA005030B1 (hu)
ES (1) ES2188285T3 (hu)
HK (1) HK1044472A1 (hu)
HU (1) HUP0104593A3 (hu)
IL (1) IL143938A0 (hu)
MX (1) MXPA01006467A (hu)
MY (1) MY121399A (hu)
NO (1) NO20013160L (hu)
NZ (1) NZ512533A (hu)
PL (1) PL348581A1 (hu)
PT (1) PT1140191E (hu)
WO (1) WO2000038729A1 (hu)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0000772D0 (sv) 2000-03-08 2000-03-08 Astrazeneca Ab Chemical compounds
WO2001068096A2 (en) * 2000-03-10 2001-09-20 Pharmacia Corporation Combination therapy for the prophylaxis and treatment of hyperlipidemic conditions and disorders
EG26979A (en) 2000-12-21 2015-03-01 Astrazeneca Ab Chemical compounds
GB0121337D0 (en) 2001-09-04 2001-10-24 Astrazeneca Ab Chemical compounds
GB0121622D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
GB0121621D0 (en) 2001-09-07 2001-10-31 Astrazeneca Ab Chemical compounds
ATE349214T1 (de) 2001-09-08 2007-01-15 Astrazeneca Ab Benzothiazepin und benzothiadiazepin derivative mit hemmender wirkung auf den säuretransport in den gallengängen zur behandlung von hyperlipidaemia
GB0209467D0 (en) 2002-04-25 2002-06-05 Astrazeneca Ab Chemical compounds
GB0213669D0 (en) 2002-06-14 2002-07-24 Astrazeneca Ab Chemical compounds
GB0304194D0 (en) 2003-02-25 2003-03-26 Astrazeneca Ab Chemical compounds
GB0307918D0 (en) 2003-04-05 2003-05-14 Astrazeneca Ab Therapeutic use
PT2637646T (pt) 2010-11-08 2016-08-17 Albireo Ab Uma combinação farmacêutica que compreende um inibidor do ibat e um sequestrador de ácido biliar
HUE030062T2 (hu) 2010-11-08 2017-04-28 Albireo Ab IBAT inhibitorok májbetegségek kezelésére
JP2012171911A (ja) 2011-02-22 2012-09-10 Kao Corp Ｐｐａｒ活性化剤
HUE053359T2 (hu) * 2012-06-15 2021-06-28 Conaris Res Institute Ag Nikotinsavat és/vagy nikotinamidot és/vagy triptofánt tartalmazó gyógyászati készítmény a bél mikrobiótájának pozitív befolyásolására
JO3301B1 (ar) 2013-04-26 2018-09-16 Albireo Ab تعديلات بلورية على إيلوبيكسيبات
KR20220082931A (ko) 2014-06-25 2022-06-17 이에이 파마 가부시키가이샤 고형 제제 및 그의 착색 방지 또는 착색 감소 방법
TWI691331B (zh) 2014-09-26 2020-04-21 日商興和股份有限公司 脂質異常症治療劑
EP3012252A1 (en) 2014-10-24 2016-04-27 Ferring BV Crystal modifications of elobixibat
US10786529B2 (en) 2016-02-09 2020-09-29 Albireo Ab Oral cholestyramine formulation and use thereof
US10441604B2 (en) 2016-02-09 2019-10-15 Albireo Ab Cholestyramine pellets and methods for preparation thereof
RU2750937C2 (ru) 2016-02-09 2021-07-06 Альбирео Аб Пероральный состав холестирамина и его применение
CA3011565C (en) 2016-02-09 2024-01-02 Albireo Ab Oral cholestyramine formulation and use thereof
US10441605B2 (en) 2016-02-09 2019-10-15 Albireo Ab Oral cholestyramine formulation and use thereof
CA3071285A1 (en) 2017-08-09 2019-02-14 Albireo Ab Cholestyramine granules, oral cholestyramine formulations and use thereof
WO2019032027A1 (en) 2017-08-09 2019-02-14 Albireo Ab CHOLESTYRAMINE TABLETS, ORAL FORMULATIONS OF CHOLESTYRAMINE AND THEIR USE
US10793534B2 (en) 2018-06-05 2020-10-06 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
WO2019234077A1 (en) 2018-06-05 2019-12-12 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
US11801226B2 (en) 2018-06-20 2023-10-31 Albireo Ab Pharmaceutical formulation of odevixibat
PE20210182A1 (es) 2018-06-20 2021-01-29 Albireo Ab Modificaciones de cristales de odexibat
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
US10722457B2 (en) 2018-08-09 2020-07-28 Albireo Ab Oral cholestyramine formulation and use thereof
US10975045B2 (en) 2019-02-06 2021-04-13 Aibireo AB Benzothiazepine compounds and their use as bile acid modulators
CN113453753A (zh) 2019-02-06 2021-09-28 阿尔比里奥公司 苯并硫氮杂环庚三烯化合物及其用作胆汁酸调节剂的用途
MX2021008981A (es) 2019-02-06 2021-09-08 Albireo Ab Compuestos de benzotiadiazepina y su uso como moduladores del acido biliar.
US10941127B2 (en) 2019-02-06 2021-03-09 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
CN114761080A (zh) 2019-12-04 2022-07-15 阿尔比里奥公司 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
CN114761018A (zh) 2019-12-04 2022-07-15 阿尔比里奥公司 苯并硫杂二氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
TW202134221A (zh) 2019-12-04 2021-09-16 瑞典商艾爾比瑞歐公司 苯并噻二氮呯化合物及其作為膽酸調節劑之用途
KR20220109450A (ko) 2019-12-04 2022-08-04 알비레오 에이비 벤조티아(디)아제핀 화합물 및 담즙산 조절제로서의 이의 용도
TW202134222A (zh) 2019-12-04 2021-09-16 瑞典商艾爾比瑞歐公司 苯并噻(二)氮呯化合物及其作為膽酸調節劑之用途
EP4069359B1 (en) * 2019-12-04 2024-01-03 Albireo AB Benzothia(di)azepine compounds and their use as bile acid modulators
TW202134218A (zh) 2019-12-04 2021-09-16 瑞典商艾爾比瑞歐公司 苯并噻氮呯化合物及其作為膽酸調節劑之用途
AR120679A1 (es) 2019-12-04 2022-03-09 Albireo Ab Compuestos de benzoti(di)azepina y su uso como moduladores ácido biliar
WO2021110886A1 (en) 2019-12-04 2021-06-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
US11014898B1 (en) 2020-12-04 2021-05-25 Albireo Ab Benzothiazepine compounds and their use as bile acid modulators
JP2023537285A (ja) 2020-08-03 2023-08-31 アルビレオ・アクチボラグ ベンゾチア（ジ）アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
JP2023549226A (ja) 2020-11-12 2023-11-22 アルビレオ エービー 進行性家族性肝内胆汁うっ滞症（ｐｆｉｃ）を処置するためのオデビキシバット
BR112023010799A2 (pt) 2020-12-04 2023-10-03 Albireo Ab Compostos de benzotia(di)azepina e seus usos como moduladores de ácidos biliares
WO2023237728A1 (en) 2022-06-09 2023-12-14 Albireo Ab Treating hepatitis

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19916108C1 (de) * 1999-04-09 2001-01-11 Aventis Pharma Gmbh Mit Zuckerresten substituierte 1,4-Benzothiazepin-1,1-dioxidderivate, Verfahren zu deren Herstellung und deren Verwendung

Also Published As

Publication number Publication date
ES2188285T3 (es) 2003-06-16
PL348581A1 (en) 2002-06-03
EA005030B1 (ru) 2004-10-28
NO20013160D0 (no) 2001-06-22
CZ20012343A3 (cs) 2001-12-12
HK1044472A1 (zh) 2002-10-25
EA200100703A1 (ru) 2001-12-24
NO20013160L (no) 2001-08-21
EP1140191A1 (en) 2001-10-10
WO2000038729A1 (en) 2000-07-06
US20030125316A1 (en) 2003-07-03
DE69903661D1 (de) 2002-11-28
IL143938A0 (en) 2002-04-21
CN1338946A (zh) 2002-03-06
MXPA01006467A (es) 2004-03-10
DK1140191T3 (da) 2003-02-24
BR9916567A (pt) 2001-12-11
DE69903661T2 (de) 2003-07-03
HUP0104593A3 (en) 2004-10-28
PT1140191E (pt) 2003-01-31
CA2356664A1 (en) 2000-07-06
MY121399A (en) 2006-01-28
ATE226448T1 (de) 2002-11-15
NZ512533A (en) 2004-02-27
EP1140191B1 (en) 2002-10-23
KR20010102963A (ko) 2001-11-17
AU776952B2 (en) 2004-09-30
JP2002533415A (ja) 2002-10-08
AU2348100A (en) 2000-07-31
AR037806A1 (es) 2004-12-09

Similar Documents

Publication Publication Date Title
HUP0104593A2 (hu) Csípőbél epesav transzport inhibitor benzotiepin- és nikotinsav-származékok kombinációi szív-érrendszeri indikációkhoz
MXPA01006472A (es) Combinaciones de inhibidores de transporte de acido biliar ileal y derivados de acido fibrico para indicaciones cardiovasculares.
HUP0104745A2 (hu) Csípőbél epesav transzport inhibitorok és epesav elvonószerek kombinációi szív-érrendszeri indikációkhoz
MXPA01006471A (es) Combinaciones de inhibidores de transporte de acido biliar ileal e inhibidores de proteina de transferencia de ester colesterilio cpara indicaciones cardiovasculares.
CA2356158A1 (en) Combinations of cholesteryl ester transfer protein inhibitors and nicotinic acid derivatives for cardiovascular indications
PT1509232E (pt) Uma combinação de um antagonista de nmda e inibidores da acetilcolina esterase para o tratamento da doença de alzheimer
AU7449598A (en) Medicinal composition for prevention or treatment of hepatopathy
ZA945425B (en) 2-amino-4-phenyl-4-oxo-butyric acid derivatives
HUP0400886A2 (hu) Koleszteril-észter transzfer protein inhibitorok és fibrinsav-származékok kombinációi szív-érrendszeri indikációkhoz
AU2157500A (en) Combinations of cholesteryl ester transfer protein inhibitors and bile acid sequestering agents for cardiovascular indications
NO20014976L (no) Dibenzoazulenderivater for behandling av trombose, osteoporose og arteriosklerose